Please login to the form below

Not currently logged in
Email:
Password:

GSK/Neurocrine depression drug fails

A potential therapy for depression developed by GlaxoSmithKline and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial

A potential new therapy for major depression that is being developed through a partnership between GlaxoSmithKline (GSK) and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial.

Top-line efficacy and safety results from a phase II trial of Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 found that the drug was no more effective than placebo in patients experiencing a major depressive episode.

The study, which was conducted by GSK, enrolled 150 patients who were randomised to receive either 350mg of GSK561679 daily or placebo. The primary endpoint was change from baseline in the Bech Melancholia scale at week six. The Bech Melancholia scale is designed to measure the severity of depressive symptoms in patients with depressive illness.

Neurocrine said it will meet with GSK once the full clinical data set is complete, which is targeted for within the next few months, to decide on the next steps for the development programme. Meanwhile, clinical trials are ongoing to test the drug as a treatment for post traumatic stress disorder, anxiety and alcoholism.

Neurocrine and GSK signed a worldwide research, development and commercialisation agreement for Corticotropin Releasing Factor Receptor Antagonists for psychiatric, neurological and gastrointestinal diseases in 2001.

15th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics